NUTRACEUTICAL INGREDIENT
COGNITIVE HEALTH
RED GINSENG HRG80™
Panax ginseng C.A. Meyer, whole root, steam-cooked
Whole-root powder from an aseptically grown ginseng root, steam-cooked so that more than 80% of its ginsenosides are rare forms. Nothing extracted, nothing added.
Positioned for cognition and stress resilience. Five human studies on this exact material, three of them randomized and double-blind.
>80%
Rare ginsenosides
3
Double-blind RCTs on HRG80
200 MG
Daily dose, largest trial
What is it
The root grows in a sealed cleanroom, without soil or pesticides. It is harvested whole, steam-cooked and milled to a free-flowing 300 µm powder. It is not an extract: nothing is taken out and nothing is added back.
Here, steaming is the point. It converts the major ginsenosides of fresh root, such as Rb1, Rg1 and Re, into rare deglycosylated forms such as Rg5, Rk1 and Rg3. Rare forms make up under 10% of the ginsenosides in white ginseng and 30 to 50% in conventional red ginseng. In HRG80 they exceed 80%, across a profile of 23 ginsenosides quantified by UHPLC.
FORM
ROOT POWDER
TOTAL GINSENOSIDES
11 TO 15%
RARE GINSENOSIDES
OVER 80%
ORIGIN
BELGIUM
WHY IT WAS DEVELOPED
In recent years, the “mental load” has emerged as a prevalent public health concern with serious consequences for health and well-being. Often associated with a “double workday”, evidence shows women are particularly affected.
Red Ginseng HRG80™ was developed for this use. Its human studies measured the factors that make up mental stamina: attention, stress, mood and recovery.
23%
of women
14%
of men
struggle with a daily heavy mental load (IPSOS France, 2018)
77%
Fatigue, of cases
63%
Stress, of cases
PROPRIETARY DATA
A summary of BOTALYS studies on HRG80, in humans, animals and cells. The asterisks give the type of study behind each result.

* Proprietary clinical trial: randomized, double-blind, crossover; 50 participants, about 418 mg/day, 14 days per arm.
** Proprietary in vivo study: aged vs young mice, 50 mg/kg/day, Y-maze test.
*** Proprietary in vitro study: neuronal excitotoxicity model, 100 µg/mL.
**** Proprietary in vitro study: rat primary hippocampal neurons, 1 µg/mL.
***** Proprietary ex vivo study: mouse hippocampus LTP model, 10 mg/kg.
****** Proprietary clinical trial: randomized, double-blind, placebo-controlled; 142 participants analysed, 200 mg/day, 3 weeks.
ATTENTION AND COGNITION
Attention on the d2 test improved versus placebo from the first day in stressed office workers, while white ginseng did not separate from placebo. Faster spatial planning at 200 mg/day, and wider frontal EEG activation during attention tasks in adults aged 60 to 75.
CLINICAL EVIDENCE
STRONG
3 randomized, double-blind trials on HRG80
STRESS AND MOOD
Perceived stress and negative affect fell more than with placebo after three weeks at 200 mg/day in 142 moderately stressed adults. In the earlier crossover trial, stress scores fell from day 5 on HRG80 and only from day 12 on white ginseng.
CLINICAL EVIDENCE
STRONG
2 randomized, double-blind trials on HRG80, against placebo and against white ginseng
PHYSICAL RECOVERY
Muscle soreness fell versus no treatment in 20 elite weightlifters over 10 days of intense training, with 400 mg/day capsules and with a 100 mg/day γ-cyclodextrin chewable. Capsules also improved push-up performance.
CLINICAL EVIDENCE
EMERGING
1 open-label crossover trial on HRG80, no placebo
STRONG, significant in two or more randomized, double-blind, controlled trials on HRG80. MODERATE, in one such trial. EMERGING, open-label human trial or preclinical data only. Every grade on this page describes studies on HRG80 itself.
STRESS, MOOD AND PLANNING IN THREE WEEKS AT 200 MG
In the largest HRG80 trial, run at UCLouvain in 149 moderately stressed adults, one 200 mg capsule a day for three weeks reduced perceived stress and negative affect more than placebo, and shortened planning time on the CANTAB One Touch Stockings task.
The reduction in depressive symptom scores did not reach significance (p = 0.073). Tolerance was good, with no serious adverse events and 98% compliance.
Randomized, double-blind, placebo-controlled, parallel groups. 149 adults aged 18 to 60 with moderate perceived stress (PSS 14 to 26), 142 analysed.
HRG80 200 mg/day or placebo for 21 days. PSS, PANAS, BDI-II and CANTAB battery.
PSS −4.3 vs −2.7 (p = 0.040). PANAS negative affect −2.6 vs −1.1 (p = 0.032). One Touch Stockings latency −1,633 ms vs −374 ms (p = 0.036).
Dormal et al., Nutrients 2025; 17: 955. NCT06414486.
ATTENTION FROM DAY ONE, AHEAD OF WHITE GINSENG
In a three-arm crossover trial in 50 office workers under occupational stress, HRG80 at about 418 mg a day improved d2 attention test performance versus placebo from the first day of intake. White ginseng at a similar dose did not separate from placebo (p = 0.65). Perceived stress fell from day 5 on HRG80 and from day 12 on white ginseng.
Randomized, double-blind, placebo-controlled, three-arm crossover. 50 healthy office workers under occupational stress, 14 days per arm.
HRG80 about 418 mg/day, white ginseng 382 mg/day, placebo. d2 attention test, memory test and PSS on days 1, 5 and 12.
Mariage et al., Pharmaceuticals 2020; 13: 57. NCT03947554. Pilot study.
Every mechanism and outcome below was measured on HRG80, in cells, tissue, animals or humans. The lines between them are proposed links, not established pathways.
Unlike the general ginseng literature, every row below describes work done on HRG80 itself. The four trials cited total about 250 subjects, with no serious adverse events.
The limits are stated too: three of these trials enrolled 50 subjects or fewer, one was open label, and the longest exposure so far is four weeks. A fifth, open-label study in a clinical population is not used for claims here. We publish this because a formulator will find it anyway.
FORMULATION
DOSES TESTED IN HUMANS
400 MG FAST ONSET
Attention from day one; cognition and EEG trials.
200 MG STANDARD
One capsule; stress, mood and planning in three weeks.
100 MG WITH CYCLODEXTRIN
Chewable; matched 400 mg capsules on muscle soreness.
The cognition and EEG trials used about 418 mg a day. Higher doses and exposures beyond four weeks have not been studied. Permitted claims depend on the market and the finished product.
Samples, specifications and the clinical dossier are available to qualified brands and formulators.
REQUEST A SAMPLE
REQUEST THE HEALTH CLAIMS MATRIX


